BCAB: BioAtla, Inc. Short-Term Debt to Equity

BioAtla Inc - graphic logo of issuer BCAB

This daily price chart for BioAtla, Inc. (BCAB) demonstrates the 0.00 metric. The business focuses on developing biologics that activate exclusively within tumor zones to minimize health risks. The company's environmental approach is based on adherence to ethical standards and the safe processing of waste. Clinical test efficiency is supported by an established express delivery system for components via a network of external laboratories.

BCAB (bioatla.com) Current Liabilities to Capital history from 07/04/2022 to 09/06/2026

Analytical breakdowns for BioAtla Corp (BCAB)

- price and consensus price forecast:
Stock Price BioAtla, Inc.|BCAB - Average Forecast Price
- market capitalization data:
Market Value BioAtla Inc|BCAB - Business Value
- book capitalization data:
Book Value per Share BioAtla|BCAB - Total Stockholders' Equity|Market Value to Book Value Ratio bioatla.com|BCAB - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital BioAtla, Inc.|BCAB - Long-Term Debt to Capital|Short-Term Debt to Equity BioAtla, Inc.|BCAB - Company Debts|Debt to Book Value BioAtla Inc
Fundamental company analysis:BioAtla, Inc.
Brand item of BioAtla, Inc.

The commercialization of cancer therapy based on CAB technology requires significant R&D investment to reduce drug toxicity. By analyzing the ratio of short-term debt to equity, an investor assesses the proportion of liabilities maturing within one year relative to equity, where a sharp increase in this metric signals a risk of rising debt service costs and potential price volatility for BioAtla, Inc. (BCAB).

Competing companies

Incyte Corp. - Short-Term Debt to Capital|Current Liabilities to Capital HCM (HUTCHMED Corp)|NUVB - Short-Term Debt to Equity|Short-Term Debt to Capital Ratio dayonebio.com DAWN|MNPR (Monopar Therapeutics Inc.) - Short-Term Debt to Capital|INBX: Current Liabilities to Capital|Short-Term Debt to Equity i-mabbiopharma.com IMAB|Fennec (FENC) - Ratio of Short-Term Indebtedness to Capital|HRTX (Heron) - Short-Term Debt to Capital|Short-Term Debt to Capital NVCT|Short-Term Debt to Equity Coherus BioSciences, Inc (CHRS)|Short-Term Debt to Equity Corbus Pharmaceuticals Holdings, Inc. CRBP|Short-Term Debt to Equity Ratio Cardiff Oncology|BeyondSpring Inc - Ratio of Short-Term Indebtedness to Capital|LIXT (Lixte Biotechnology) - Short-Term Debt to Equity|CTXR: Current Liabilities to Capital|Short-Term Debt to Equity Cellectar Biosciences, Inc.|BioLineRx Ltd (BLRX) - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CANF|Short-Term Debt to Equity Ratio APRE|Kazia Therapeutics - Short-Term Debt to Equity|Current Liabilities to Capital SLXN (silexion.com)|Short-Term Debt to Equity NuCana NCNA|Chimerix Inc. - Short-Term Debt to Equity|CYCC (Cyclacel Pharmaceuticals Inc.) - Short-Term Debt to Equity|GTHX - Current Liabilities to Capital|Short-Term Debt to Capital KRON (Kronos Bio, Inc.)|Short-Term Indebtedness to Equity kintara.com|Short-Term Debt to Equity Ratio ONCT (Oncternal Therapeutics, Inc.)|Current Liabilities to Capital Portage Biotech Inc (PRTG)